Nanobiotix (NASDAQ:NBTX) Shares Gap Down – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s share price gapped down before the market opened on Wednesday . The stock had previously closed at $26.43, but opened at $25.35. Nanobiotix shares last traded at $24.2620, with a volume of 19,067 shares changing hands.

Analyst Ratings Changes

NBTX has been the topic of a number of research reports. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. TD Cowen initiated coverage on shares of Nanobiotix in a report on Friday, February 6th. They issued a “buy” rating for the company. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Guggenheim increased their target price on Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Wall Street Zen upgraded Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Trading Up 3.5%

The stock’s 50 day simple moving average is $21.93 and its two-hundred day simple moving average is $17.83.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Marshall Wace LLP purchased a new stake in shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 9,500 shares of the company’s stock, valued at approximately $220,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.